Krystal Biotech price to free cash flow KRYS

Market value divided by free cash flow over the last twelve months, since 2024.

Today, Oct 23, 2026: 35.8×
Peer median: 21.8×

Krystal Biotech's price to free cash flow is 35.8× as of Oct 23, 2026.

The median for 10 biotech stocks of a similar size is 21.8×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	35.8×	35.8×	49.9×
2025	44.2×	21.6×	79.1×
2024	78.9×	78.9×	98.9×

Against its peers

Companies in Biotechnology nearest Krystal Biotech's size, closest first, today.

Company	Price to free cash flow
KRYSKrystal Biotech	35.8×
RGENRepligen	89.2×
TECHBIO-TECHNE	43.2×
HALOHalozyme Therapeutics	17.7×
NBIXNeurocrine Biosciences	16.7×
EXELExelixis	13.6×
INCYIncyte	12.2×
UTHRUnited Therapeutics	23.1×
ALNYAlnylam Pharmaceuticals	37.8×
ADMAAdma Biologics	20.5×
VCELVericel	35.3×
Peer median	21.8×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Krystal Biotech

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.